MRK240719C170000
- 0.01
- 0.000.00%
Merck & Co Newsroom
Goldman Sachs Adjusts Price Target on Merck & Company to $145 From $144
Merck & Company (MRK) has an average outperform rating and a price target range of $120 to $155, according to analysts polled by Capital IQ.Price: 128.22, Change: +0.10, Percent Change: +0.08
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $140
Wells Fargo analyst Mohit Bansal maintains $Merck & Co(MRK.US)$ with a hold rating, and maintains the target price at $140.According to TipRanks data, the analyst has a success rate of 63.9% and a
Jeito Capital Consolidates Its Support in CatalYm With a Renewed Participation in a $150 Million Financing
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Sen. Bernie Sanders (I-Vt.) recently expressed his concerns about the high cost of medical care in the United States, highlighting the financial burden it places on patients.
Merck & Co., Inc. (NYSE:MRK) Is Favoured by Institutional Owners Who Hold 78% of the Company
Key Insights Given the large stake in the stock by institutions, Merck's stock price might be vulnerable to their trading decisions The top 25 shareholders own 45% of the company Using data from
Trump's Betting Election Odds Surge After Assassination Attempt, How Would The Market React?
On Saturday, Donald Trump was shot at a campaign rally in Pennsylvania, which could be a key moment that completely disrupts the US election landscape this year. Following the incident, data from Polymarket shows that Trump's chances of winning the election have skyrocketed to 71%.
Express News | Merck & Co Inc : Guggenheim Cuts Target Price to $142 From $146
The Zacks Analyst Blog Highlights Exxon Mobil, Merck & Co, Qualcomm and Armanino Foods of Distinction
Concept stocks take off across the board! Trump's company surged more than 70% before the market opened, and Tesla also soared!
I won!
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
Healthcare Sector at an 'Inflection Point': Strategist
Top Research Reports for Exxon Mobil, Merck & Qualcomm
Unusual Options Activity: RDDT, GXO and Others Attract Market Bets, RDDT V/OI Ratio Reaches 200.2
EST Jul 12th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Merck's Acquisition of EyeBio Finalized
Merck (NYSE:MRK) is trending on Friday. The company announced the acquisition of EyeBio, introducing a novel candidate to Merk's pipeline, Restoret.What To Know: Restoret has shown promising results
Novo's Ozempic Linked to Improved Brain Health: Study
Sector Update: Health Care Stocks Mixed Premarket Friday
Health care stocks were mixed premarket Friday with the Health Care Select Sector SPDR Fund (XLV) down 0.2% and the iShares Biotechnology ETF (IBB) up almost 1% recently.Immutep (IMMP) rose past 17%
Investors in Merck (NYSE:MRK) Have Seen Notable Returns of 81% Over the Past Three Years
Sector Update: Health Care
Health care stocks were mixed premarket Friday with the Health Care Select Sector SPDR Fund (XLV) down 0.8% and the iShares Biotechnology ETF (IBB) 0.6% higher recently.Immutep (IMMP) shares rose
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
Friday, Immutep Limited (NASDAQ:IMMP) released results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase 2b trial of eftilagimod alfa (efti) in combination with Merck & Co Inc (NYSE:MRK) Keytruda (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expression.
Express News | Merck & Co Inc - Will Record Charge of About $1.3 Bln, or About $0.50 per Share in Q3 of 2024, Which Will Be Included in Non-Gaap Results